ATE405575T1 - Verwendung von an polyamid gebundenen nukleinsäure-oligomeren zur erzeugung einer biologischen reaktion - Google Patents

Verwendung von an polyamid gebundenen nukleinsäure-oligomeren zur erzeugung einer biologischen reaktion

Info

Publication number
ATE405575T1
ATE405575T1 AT98953610T AT98953610T ATE405575T1 AT E405575 T1 ATE405575 T1 AT E405575T1 AT 98953610 T AT98953610 T AT 98953610T AT 98953610 T AT98953610 T AT 98953610T AT E405575 T1 ATE405575 T1 AT E405575T1
Authority
AT
Austria
Prior art keywords
pna oligomers
materials
provides methods
oligomers
biological
Prior art date
Application number
AT98953610T
Other languages
English (en)
Inventor
Elliott Richelson
Beth Tyler
Daniel Mccormick
Bernadette Cusack
Clark Hoshall
Christopher Douglas
Karen Jansen
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/953,269 external-priority patent/US6472209B1/en
Priority claimed from US09/168,791 external-priority patent/US6723560B2/en
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE405575T1 publication Critical patent/ATE405575T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98953610T 1997-10-17 1998-10-16 Verwendung von an polyamid gebundenen nukleinsäure-oligomeren zur erzeugung einer biologischen reaktion ATE405575T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/953,269 US6472209B1 (en) 1997-10-17 1997-10-17 Using polyamide nucleic acid oligomers to engender a biological response
US09/016,685 US6743627B1 (en) 1997-10-17 1998-01-30 Using polyamide nucleic acid oligomers to engender a biological response
US16851998A 1998-10-08 1998-10-08
US09/168,791 US6723560B2 (en) 1998-10-08 1998-10-08 Using polyamide nucleic acid oligomers to engender a biological response
US09/168,714 US6989270B1 (en) 1997-10-17 1998-10-08 Using polyamide nucleic acid oligomers to engender a biological response

Publications (1)

Publication Number Publication Date
ATE405575T1 true ATE405575T1 (de) 2008-09-15

Family

ID=27533701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98953610T ATE405575T1 (de) 1997-10-17 1998-10-16 Verwendung von an polyamid gebundenen nukleinsäure-oligomeren zur erzeugung einer biologischen reaktion

Country Status (12)

Country Link
US (1) US6989270B1 (de)
EP (1) EP1042349B1 (de)
JP (1) JP2003523307A (de)
AT (1) ATE405575T1 (de)
AU (1) AU741246B2 (de)
BR (1) BR9814866A (de)
CA (1) CA2306731A1 (de)
DE (1) DE69839921D1 (de)
DK (1) DK1042349T3 (de)
ES (1) ES2312192T3 (de)
IL (1) IL135705A0 (de)
WO (1) WO1999020643A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472209B1 (en) 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6723560B2 (en) 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
AU2002243438A1 (en) 2000-10-25 2002-07-24 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5661386A (en) 1985-03-15 1986-10-13 Stirchak, E. Stereoregular polynucleotide-binding polymers
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5470974A (en) 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
US5783682A (en) 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5641625A (en) 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
WO1998053801A1 (en) 1997-05-28 1998-12-03 Isis Pharmaceuticals, Inc. Conjugated peptide nucleic acids having enhanced cellular uptake
WO1995004749A1 (en) 1993-08-05 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating metabolic function
WO1995004748A1 (en) 1993-08-09 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating viral processes
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
GB2284209A (en) 1993-11-25 1995-05-31 Ole Buchardt Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template
US5703067A (en) * 1995-05-08 1997-12-30 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996035705A1 (en) 1995-05-10 1996-11-14 Isis Pharmaceuticals, Inc. Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
GB9608803D0 (en) 1996-04-27 1996-07-03 Univ Newcastle Mitochondrial dna defects
AU741546B2 (en) 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6300318B1 (en) 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
WO1999013719A1 (en) 1997-09-18 1999-03-25 Gene Therapy Systems, Inc. Chemical modification of dna using peptide nucleic acid conjugates
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6472209B1 (en) * 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response

Also Published As

Publication number Publication date
WO1999020643A9 (en) 1999-08-05
AU741246B2 (en) 2001-11-29
EP1042349A1 (de) 2000-10-11
JP2003523307A (ja) 2003-08-05
US6989270B1 (en) 2006-01-24
EP1042349B1 (de) 2008-08-20
CA2306731A1 (en) 1999-04-29
WO1999020643A1 (en) 1999-04-29
DK1042349T3 (da) 2008-11-10
AU1094099A (en) 1999-05-10
ES2312192T3 (es) 2009-02-16
DE69839921D1 (de) 2008-10-02
IL135705A0 (en) 2001-05-20
BR9814866A (pt) 2001-11-20
EP1042349A4 (de) 2004-07-28

Similar Documents

Publication Publication Date Title
ATE246361T1 (de) Verfahren zur bestimmung von ige
ATE237133T1 (de) Assays zur bestimmung von proteinfragmenten in biologischen medien
DE60035691D1 (de) Verfahren zur Erkennung von Einzel-Nukleotid-Polymorphismen
SE0003286D0 (sv) Method and kit for human identification
DE69735445D1 (de) Abspaltbare, nicht-flüchtige moleküle zur massenmarkierung
ATE529509T1 (de) Selektion von proteinen unter verwendung von rna- protein-fusionen
ATE335845T1 (de) Elektrophoretische analyse von molekülen mit immobilisierten sonden
DE60029092D1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
ATE310819T1 (de) Säugetieren apoptosis inhibitorprotein genfamilie,primers, probes und verfahren zur nachweis
ATE410683T1 (de) Glukosebiosensor
DE60118527D1 (de) Sensible und multiplexe diagnostische tests zur proteinanalyse
DE60038127D1 (de) Methoden und syteme zur überwachung intrazellulärer bindereaktionen
ATE397251T1 (de) Verfahren für das entwerfen von kleinen erythropoietin mimetika
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
ATE377074T1 (de) Methode zur bereitstellung von dna sequenzen
DE3779706D1 (de) Enzymsensor zur bestimmung von glutaminat-konzentration.
ATE309333T1 (de) Synthetische polynukleotide
ATE318930T1 (de) Nukleinsäuresonden zur detektion von candida- spezies
PT696642E (pt) Processo para a identificacao de pertuebacoes do sistema proteina c / proteina s
DE59408917D1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
ATE405575T1 (de) Verwendung von an polyamid gebundenen nukleinsäure-oligomeren zur erzeugung einer biologischen reaktion
EP1083980A4 (de) Modulation molekularer wechselwirkungspositionen in rns und anderen biomolekülen
DE59814359D1 (de) Mikrostrukturierter biosensor, verwendung des biosensors und verfahren zur immobilisierung von biokatalysatoren
EP0990901A3 (de) Computergestützte Identifizierung von Paraproteinen
AU4981093A (en) Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties